SVF
Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Efficacy of Stem Cell Application in Diabetes Mellitus: Promising Future Therapy for Diabetes and Its Complications

Bani Hamad FR., Rahat N., Shankar K., Tsouklidis N.

Narrative Review with a reported sample of 120 on Type 1 Diabetes, Type 2 Diabetes, published in Cureus (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cureus (2021)
Reported sample size
120
Source database
Europe PMC
PMID
33815977
PMCID
PMC8007200
DOI
10.7759/cureus.13563
Citations
12

Abstract (original English)

Diabetes mellitus (DM) is a serious and common chronic disease with high morbidity and mortality rates. Recently, stem cell-based therapy has shown considerable promise as a future therapeutic modality for DM. This review aims to summarize the types of stem cells that have the most successful evidence in treating type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and also to assess the safety and efficacy of different types of stem cells in the treatment of DM. PubMed, MEDLINE, and PubMed Central databases were searched up to October 15, 2020, using medical subject heading (MeSH) terms. After application of inclusion criteria and exclusion criteria, 10 studies were included in our final review: six T1DM studies including 120 patients, and four T2DM studies including 65 patients. Our data showed that autologous and allogeneic stem cell therapy is a relatively safe and effective method for selected individuals with DM. The best therapeutic outcome was achieved by transplantation of bone marrow hemopoietic stem cells (BM-HSCs) for T1DM and bone marrow mononuclear cells (BM-MNCs) along with mesenchymal stromal cells (MSCs) for T2DM. However, patients with DKA are not a good candidate for stem cell transplantation. Further rigorous experiments are needed in order to be able to establish stem cell-based therapies as the future standard of care for treating DM.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Systemic / IVType 1 DiabetesType 2 Diabetes
View on PubMedFull text on Europe PMCDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “efficacy stem application”View all: author baniView all: year 2021

Related research